BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18212755)

  • 1. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
    Tibaldi C; Vasile E; Antonuzzo A; Di Marsico R; Fabbri A; Innocenti F; Tartarelli G; Amoroso D; Andreuccetti M; Lo Dico M; Falcone A
    Br J Cancer; 2008 Feb; 98(3):558-63. PubMed ID: 18212755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
    Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
    Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
    De Castro J; Lorenzo A; Morales S; Belón J; Dorta J; Lizón J; Madroñal C; Gallurt PM; Casado E; Feliu J; Barón MG;
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):197-202. PubMed ID: 15322824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
    Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
    Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
    Pectasides D; Aspropotamitis A; Halikia A; Visvikis A; Antoniou F; Kalantaridou A; Karvounis N; Batzios S; Athanassiou A
    J Clin Oncol; 1999 Dec; 17(12):3816-21. PubMed ID: 10577854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
    Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
    Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.
    Tibaldi C; Camerini A; D'Incecco A; Vasile E; Fabbri A; Amoroso D; Cappuzzo F
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2003-8. PubMed ID: 22767317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA;
    Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
    Galetta D; Gebbia V; Giotta F; Durini E; Romito S; Borsellino N; Cazzato C; Pezzella G; Colucci G
    Lung Cancer; 2002 Oct; 38(1):79-84. PubMed ID: 12367797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
    Neubauer MA; Garfield DH; Kuerfler PR; Raju RN; Lindquist DL; Soo EW; Khan M; Boehm KA; Asmar L;
    Lung Cancer; 2005 Jan; 47(1):121-7. PubMed ID: 15603862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
    Georgoulias V; Kouroussis C; Androulakis N; Kakolyris S; Dimopoulos MA; Papadakis E; Bouros D; Apostolopoulou F; Papadimitriou C; Agelidou A; Hatzakis K; Kalbakis K; Kotsakis A; Vardakis N; Vlachonicolis J
    J Clin Oncol; 1999 Mar; 17(3):914-20. PubMed ID: 10071284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.